



## Schering-Plough Extends Joint Research Program with Shanghai Genomics

**TOKYO, September 29, 2009** - GNI Ltd. a clinical-stage biopharmaceutical company, announced today that its fully owned subsidiary in China, Shanghai Genomics has reached an agreement with Schering-Plough to extend the research program started in 2006 (which was established with former Organon, now part of Schering-Plough). The program will continue to focus on nuclear receptor function and small molecule compound inhibitors.

Dr. Ying Luo, President and CEO of GNI and Shanghai Genomics said, "We are very happy that Schering-Plough continued to partner with us in Asia. Moving forward, Shanghai Genomics of GNI will leverage upon its leading position in discovery biology research in China to capture new opportunities by expanding its contract research program."

Discovery biology research has been the core competence of GNI since the company was first founded back in 2001. It has developed a comprehensive program on drug target discovery and validation in the fields of cancer and inflammation research. With its experience, GNI is well positioned in the field as international pharmaceutical corporations are now looking at outsourcing in China as a cost effective option to expand their drug development capacity.

### **About GNI**

Founded in 2001, GNI, Ltd. is a clinical-stage international drug development company with its headquarters in Tokyo, Japan, and research operations in Shanghai, China. In June 2005, GNI acquired Shanghai Genomics, which was also founded in 2001, and currently operates an integrated drug discovery and development platform in Shanghai. The combined strengths of GNI and Shanghai Genomics have resulted in research collaborations with major international pharmaceutical companies. For further information, please visit [www.qnipharma.com](http://www.qnipharma.com) and [www.shanghaigenomics.com](http://www.shanghaigenomics.com).

### **For further inquiries**

Shinobu Tanaka	Tel: +81 (03) 3580-0751 Email: <a href="mailto:ir@gene-networks.com">ir@gene-networks.com</a>
Ying Luo	Tel: +86 1381-769-8961 Email: <a href="mailto:bd@shanghaigenomics.com">bd@shanghaigenomics.com</a>

This press release contains "forward-looking" statements, including statements related to GNI's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "expected to," "will," "intend to," "strive to" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause GNI's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. GNI does not undertake any obligation to update forward-looking statements.